Comparing Ernexa Therapeutics (NASDAQ:ERNA) and Aditxt (NASDAQ:ADTX)

Ernexa Therapeutics (NASDAQ:ERNA) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for Ernexa Therapeutics and Aditxt, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1	0	0	0	1.00
Aditxt	1	0	0	0	1.00

Profitability

This table compares Ernexa Therapeutics and Aditxt’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-1,950.55%	-304.60%
Aditxt	-684,001.00%	-461.78%	-80.55%

Insider & Institutional Ownership

70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 1.5% of Ernexa Therapeutics shares are owned by insiders. Comparatively, 0.0% of Aditxt shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Ernexa Therapeutics has a beta of 6.41, indicating that its stock price is 541% more volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.

Earnings and Valuation

This table compares Ernexa Therapeutics and Aditxt”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$1,000.00	2,238.89	-$44.54 million	($3.01)	-0.09
Aditxt	$130,000.00	2.57	-$34.45 million	($1,387.93)	0.00

Aditxt has higher revenue and earnings than Ernexa Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Summary

Ernexa Therapeutics beats Aditxt on 6 of the 11 factors compared between the two stocks.

About Ernexa Therapeutics

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

About Aditxt

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.